Intra-arterial tenecteplase for treatment of acute ischemic stroke: Feasibility and comparative outcomes

Journal of Neuroimaging

Volumn 22, Issue 3, 2012, Pages 249-254

  Georgiadis, Alexandros L ^a   Memon, Muhammad Zeeshan ^a   Shah, Qaisar A ^a   Vazquez, Gabriela ^a   Tariq, Nauman A ^a   Suri, M Fareed K ^a   Taylor, Robert A ^a   Qureshi, Adnan I ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Alteplase; Intra arterial; Ischemic stroke; Reteplase; Tenecteplase; Thrombectomy; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; RETEPLASE; TENECTEPLASE;

AGED; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMPARATIVE STUDY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MECHANICAL THROMBECTOMY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; RANKIN SCALE; RECANALIZATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; BRAIN ISCHEMIA; COMORBIDITY; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; MALE; MINNESOTA; PREVALENCE; RISK ASSESSMENT; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84863777026     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2011.00628.x     Document Type: Article

References (29)

1. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716-722.
2. Lapchak PA, Araujo DM, Zivin JA. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol 2004;185:154-159.
3. Chapman DF, Lyden P, Lapchak PA, et al. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 2001;32:748-752.
4. Haley EC, Jr., Lyden PD, Johnston KC, Hemmen TM. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005;36:607-612.
5. Parsons MW, Miteff F, Bateman GA, et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 2009;72:915-921.
6. Qureshi AI, Ali Z, Suri MF, et al. Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery 2001;49:41-48; discussion 48-50.
7. Qureshi AI, Janjua N, Kirmani JF, et al. Mechanical disruption of thrombus following intravenous tissue plasminogen activator for ischemic stroke. J Neuroimaging 2007;17:124-130.
8. Qureshi AI, Alkawi A, Hussein HM, et al. Angiographic analysis of intravascular thrombus volume in patients with acute ischemic stroke. J Endovasc Ther 2007;14:475-482.
9. Qureshi AI, Siddiqui AM, Suri MF, et al. Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery 2002;51:1319-1327; discussion 27-29.
10. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004;35:904-911.
11. Gobin YP, Starkman S, Duckwiler GR, et al. MERCI 1: a phase 1 study of mechanical embolus removal in cerebral ischemia. Stroke 2004;35:2848-2854.
12. Qureshi AI. New grading system for angiographic evaluation of arterial occlusions and recanalization response to intra-arterial thrombolysis in acute ischemic stroke. Neurosurgery 2002;50:1405-1414; discussion 1414-5.
13. Lijnen R, Collen D. Mollecular and cellular basis of fibrinolysis. In: Hoffman R, Benz Jr. EJ, Shattil SJ, et al., eds. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, PA: Churchill Livingstone; 2009:1837-41.
14. Qureshi AI, Pande RU, Kim SH, et al. Third generation thrombolytics for the treatment of ischemic stroke. Curr Opin Investig Drugs 2002;3:1729-1732.
15. Baker WF, Jr. Thrombolytic therapy: current clinical practice. Hematol Oncol Clin North Am 2005;19:147-181, vii.
16. Serebruany VL, Malinin AI, Callahan KP, et al. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. Am Heart J 2003;145:636-642.
17. Stewart RJ, Fredenburgh JC, Leslie BA, et al. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. J Biol Chem 2000;275:10112-10120.
18. Benedict CR, Refino CJ, Keyt BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995;92:3032-3040.
19. Dunn CJ, Goa KL. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. Am J Cardiovasc Drugs 2001;1:51-66.
20. Toombs CF. New directions in thrombolytic therapy. Curr Opin Pharmacol 2001;1:164-168.
21. Refino CJ, Paoni NF, Keyt BA, et al. A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost 1993;70:313-319.
22. Szabo S, Letsch R, Ehlers R, et al. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase. Thromb Res 2002;106:113-119.
23. De Marco E, Andreotti F, van de Greef W, et al. The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA. Cardiologia 1998;43:1209-1213.
24. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95:351-356.
25. Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998;98:2805-2814.
26. Van de Werf F, Cannon CP, Luyten A, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J 1999;137:786-791.
27. Melandri G, Vagnarelli F, Calabrese D, et al. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag 2009;5:249-256.
28. Goodman SG, Menon V, Cannon CP, et al. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:708S-775S.
29. Georgiadis AL, Hussein HM, Vazquez G, et al. Premorbid use of statins is associated with higher recanalization rates in patients with acute ischemic stroke undergoing endovascular treatment. J Neuroimaging 2009;19:19-22.